CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas

CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas

BackgroundCDK4/6 inhibitors (CDK4/6i) have been established as standard treatment against advanced Estrogen Receptor-positive breast cancers. These drugs are being tested against several cancers, including in combinations with other therapies. We identified the T172-phosphorylation of CDK4 as the st...

Full description

Bibliographic Details
Main Authors: Jaime M. Pita, Eric Raspé, Katia Coulonval, Myriam Decaussin-Petrucci, Maxime Tarabichi, Geneviève Dom, Frederick Libert, Ligia Craciun, Guy Andry, Laurence Wicquart, Emmanuelle Leteurtre, Christophe Trésallet, Laura A. Marlow, John A. Copland, Cosimo Durante, Carine Maenhaut, Branca M. Cavaco, Jacques E. Dumont, Giuseppe Costante, Pierre P. Roger
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Endocrinology
Subjects:
ATC
PDTC
CDK4 Thr172-phosphorylation
palbociclib
trametinib
dabrafenib
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2023.1247542/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2023.1247542/full

Similar Items